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Hepatocellular carcinoma is rapidly becoming one of the leading causes of cancer-related deaths, 
largely due to the increasing incidence of non-alcoholic fatty liver disease. This in part may be 
attributed to Westernised diets high in fructose sugar. While many studies have shown the effects of 
fructose on inducing metabolic-related liver diseases, little research has investigated the effects of 
fructose sugar on liver cancer metabolism. The present study aimed to examine the metabolic effects 
of fructose on hepatocellular carcinoma growth in vitro and in vivo. Fructose sugar was found to 
reduce cell growth in vitro, and caused alterations in the expression of enzymes involved in the serine-
glycine synthesis and pentose phosphate pathways. These biosynthesis pathways are highly active 
in cancer cells and they utilise glycolytic by-products to produce energy and nucleotides for growth. 
Hence, the study further investigated the efficacy of two novel drugs that inhibit these pathways, 
namely NCT-503 and Physcion. The study is the first to show that the combination treatment of 
NCT-503 and Physcion substantially inhibited hepatocellular carcinoma growth in vitro and in vivo. 
The combination of fructose diet and metabolism-inhibiting drugs may provide a unique metabolic 
environment that warrants further investigation in targeting hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) remains a universal health burden as it is the fourth leading cause of cancer-
related  deaths1. Although viral hepatitis and alcoholism account for a large majority of the HCC cases, there is 
an alarming increase in the incidence of HCC relating to non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH)2. Prediction models suggest that the incidence of NAFLD/NASH-related HCC 
cases will increase 146% by 2030 in the United  States3, and European countries show similar patterns of increasing 
prevalence of this  disease4. This steep increase of HCC incidence will occur not just due to the aging population, 
but also as a result of the increasing prevalence of obesity and type 2 diabetes mellitus (DM).
Many have attributed the rise in obesity and DM to the overconsumption of sugar-rich foods associated with 
the Westernised diet. Particularly, the overconsumption of fructose sugar has been considered a major contrib-
uting factor to NAFLD development by causing increased liver de novo lipogenesis, inflammation and insulin 
 resistance5. Several preclinical studies have suggested that fructose-rich diets can increase HCC incidence and 
tumour  burden6–9. Furthermore, genetic analyses suggest that fructose induces metabolic changes to glycolysis 
that may fuel tumour  growth10,11. Of unknown value are the contributions of fructose metabolism to the pentose 
phosphate pathway (PPP) and serine to glycine synthesis pathway (SGS), which are responsible for using glyco-
lytic by-products to produce nucleotides and NADPH for cell growth and proliferation. The effects of fructose 
consumption on activating these pathways in HCC has yet to be fully evaluated.
Part of the burden of HCC can be attributed to the poor survival rate due to late state diagnoses, leaving very 
few treatment options. While there are approved drugs available for treating advanced stage disease such as 
Sorafenib, Regaforenib, and Lenvatinib, they are non-curative options and only extend life by 10–14 months12. 
With the growing incidence of HCC cases relating to obesity and NAFLD, and little advancements in the field 
of curative treatment, there is an urgent clinical need for novel therapeutic approaches in HCC therapy. Phy-
scion is a naturally derived anti-cancer drug that inhibits the second enzymatic step in the PPP by blocking 
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6-phosphogluconate dehydrogenase (6PGD). Some recent studies have shown Physcion to be effective in reduc-
ing HCC growth in vitro13,14, yet no studies have investigated these effects in vivo, or in the combination of 
fructose supplementation. NCT-503 is a synthetic compound that inhibits the first enzymatic step of the SGS by 
blocking phosphoglycerate dehydrogenase (PHGDH). Currently only one study has investigated the effects of 
NCT-503 on HCC, demonstrating significant effects on reducing HCC growth in Sorafenib resistant  tumours15.
In this study we investigated the effects of fructose on HCC cell growth in vitro and in vivo. Furthermore, 
we demonstrate for the first time the effects of PPP and SGS pathway inhibition using Physcion and NCT-503, 
respectively, in glucose and fructose grown HCC. Our results demonstrate that fructose induces metabolic 
changes in HCC growth, resulting in HCC cell death in vitro and varying drug response to metabolism inhibiting 
compounds in vivo. Moreover, the combination of both Physcion and NCT-503 caused a significant reduction 
of HCC tumour growth in vivo. In conclusion, we propose a novel role for fructose metabolism in HCC, and 
demonstrate that together with metabolism-inhibiting drugs, could represent a novel therapeutic strategy for 
treating NAFLD-related HCC.
Results
Fructose restricts HCC proliferation and induces metabolic changes to the PPP and SGS path-
ways. Murine primary HCC cells, named A52, that we previously  developed16, and human HCC Huh7 cells 
were used to study the effects of HCC growth in glucose and fructose supplemented media. Cells were cultured 
in glucose or fructose supplemented media and cell proliferation evaluated after 24, 48 and 72 h. Compared to 
glucose, HCC cells grown in fructose had significantly reduced cell proliferation (p < 0.05; Fig. 1a,b). Similarly, 
A52 and Huh7 subcutaneous tumour formation was respectively, slightly delayed or showed slower growth in 
mice fed a high fructose chow compared to those fed the normal chow (Fig. 1c,d). To explore the metabolic dif-
ferences in glucose and fructose grown HCC, protein expression of enzymes involved in the PPP and SGS were 
evaluated from cell and tumour lysates. Fructose treated HCC cells showed little changes in expression of the 
SGS and PPP pathways (Fig. 1e,f and Supplementary Figures 2 and 4). However, through dietary intake fruc-
tose increased expression of the SGS rate limiting enzyme, PHGDH, as well as the second SGS enzyme PSAT1 
(phosphoserine aminotransferase1), in A52 and Huh7 tumours (Fig. 1g,h and Supplementary Figures 6 and 
8). Enzymes of the non-oxidative branch of the PPP, namely transketeloase (TKT) and transaldolase (TALDO) 
remained unchanged in vivo. Interestingly, the expression of glucose-6-phosphate dehydrogenase (G6PD), the 
rate limiting enzyme of the oxidative branch of the PPP, was upregulated in fructose A52 tumours (Fig. 1g and 
Supplementary Figure 6), while downregulated in the Huh7 fructose group (Fig. 1h and Supplementary Fig-
ure 8).
The PPP is upregulated in HCC and is associated with poor patient survival. To determine the 
association of the PPP and SGS pathways in clinical HCC, we analysed PHGDH, PSAT1 and G6PD RNA expres-
sion in HCC tumour and non-tumour liver tissue from the Cancer Genome Atlas (TCGA) liver hepatocellular 
carcinoma (LIHC) database. We also considered the second enzyme of the PPP pathway, 6PGD (6-phosphoglu-
conate dehydrogenase), as it represents a novel HCC metabolic target. Between the two groups, tumour tissue 
had significantly upregulated G6PD (p < 0.0001), unaltered 6PGD, and PHGDH and PSAT1 were significantly 
downregulated (p < 0.0001), versus the non-tumour tissue (Fig. 2a). Considering survival, patients with high 
expression of either G6PD or 6PGD have significantly decreased overall survival compared to those with low or 
medium expression (p < 0.01). With regards to PHGDH or PSAT1, there was no difference in overall survival for 
patients with low, medium, or high expression (Fig. 2b).
Fructose-grown HCC is inhibited by NCT-503 and Physcion in vitro. As our in vivo tumour data 
and bioinformatic analyses suggested relationships between the PPP and SGS on HCC growth, we inhibited 
the PPP and SGS with Physcion and/or NCT-503, respectively, and determined A52 and Huh7 cell prolifera-
tion under glucose and fructose conditions. Consistent with previous results, fructose grown HCC cells had 
reduced growth compared to normal and glucose grown cells (Fig. 3). Importantly, after 24 and 48 h, both A52 
and Huh7 cells treated with fructose and either NCT-503, Physcion, or in combination significantly reduced cell 
proliferation compared to glucose (p < 0.0001). A52 cells treated with glucose and increasing concentrations of 
NCT-503 and Physcion (25 and 50 μM) had significantly reduced growth compared to control at 24 and 48 h 
(p < 0.01; Fig. 3a,b). Unexpectedly, Huh7 cells had increased proliferation in the presence of Physcion and glu-
cose, while combination treatment diminished growth similarly to that seen with NCT-503 alone (Fig. 3c,d). 
In contrast to A52 cells, Huh7 growth was significantly reduced after 48 h of exposure to low concentrations of 
NCT-503 (p < 0.001; Fig. 3b,d). This data is supported by tumoursphere assays of A52 and Huh7 cells. Fructose 
alone dramatically reduced sphere number in A52 and Huh7 cells (Fig. 3e,f). Similarly, Huh7 tumoursphere 
number increased in the presence of Physcion and glucose, while NCT-503 significantly reduced sphere forma-
tion (p < 0.0001; Fig. 3f). Collectively, these results suggest A52 cells are more sensitive to PPP inhibition, while 
in contrast Huh7 cells are more affected by SGS inhibition, and the effect of metabolic pathway inhibition in 
conjunction with fructose feeding is detrimental for HCC cell growth in vitro.
Fructose induces apoptosis in HCC in vitro. To investigate the mechanism by which fructose reduced 
cell proliferation in vitro, A52 and Huh7 cells grown in glucose or fructose were stained with Annexin V and 
7-AAD, and analysed with flow cytometry. Control apoptosis was induced with  H2O2 (Fig. 4b,h). Compared to 
control cells grown in normal media, glucose treated cells had similar cell viability for A52 (Fig. 4a,c) and Huh7 
cells (Fig. 4g,i). In contrast, fructose promoted a 2.6-fold increase in A52 apoptotic cells (Fig. 4d), and an 8.8-
fold increase in Huh7 apoptotic cells (Fig. 4j). Histogram plots show a strong second peak shift for FITC and 
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Figure 1.  Evaluating A52 and Huh7 HCC growth and protein expression in glucose and fructose conditions. Cell proliferation 
via a BrdU assay was determined for (a) A52 cells, and (b) Huh7 cells grown in media containing 5 mM glucose or 5 mM 
fructose over 24, 48 and 72 h. Growth of (c) A52 and (d) Huh7 tumours was evaluated in mice fed a normal or high-fructose 
chow. Western blots of cell lysates for TKT, TALDO, PHGDH, G6PD, PSAT1 and β-actin from, (e) A52 cells, and (f) Huh7 
cells growth in glucose or fructose containing media for 24 and 48 h, and tumour lysates from (g) A52, and (h) Huh7 (H) 
subcutaneous tumours in mice fed a normal chow or high fructose diet. Original blots and densitometry analysis for the in vitro 
protein analysis and in vivo protein analysis are shown in Supplementary Figures 1–8 (Supplementary File 1). Full length 
western blot images for TKT, TALDO, PHGDH, PSAT1 and β-actin could not be provided for (e) and (g). These images were 
provided from the thesis of M.A., and full-length original images could not be obtained. The original images in this figure and 
the Supplementary File are as presented in the thesis of M.A. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. G6PD glucose-
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Figure 2.  Evaluation of the PPP and SGS in human HCC. (a) Gene expression of G6PD, 6PGD, PHGDH, 
and PSAT1 was determined in HCC tumour tissue (n = 371) and normal liver tissue (n = 50). Boxplots show 
median represented by the horizontal line and the box boundaries represent the first and third quartile range. 
The whiskers are derived from the Tukey method. (b) Patients were sorted into percentiles of low, medium, 
and high expression of G6PD (low n = 38, medium n = 293, high n = 39), 6PGD (low n = 38, medium n = 292, 
high n = 40), PHGDH (low n = 38, medium n = 292, high n = 40), and PSAT1 (low n = 38, medium n = 191, high 
n = 40), and graphs represents overall patient survival in low, medium, and high expression groups. *p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001. 6PGD 6-phosphogluconate dehydrogenase, G6PD glucose-6-phosphate 
dehydrogenase, PHGDH phosphoglycerate dehydrogenase, PSAT1 phosphoserine aminotransferase 1.
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Figure 3.  A52 and Huh7 cell proliferation with NCT-503 and Physcion. Cell proliferation was determined 
using the BrdU assay in cells grown in either normal media, media containing 5 mM glucose or 5 mM fructose, 
with or without 10, 25, or 50 μM of NCT-503 and/or Physcion. Graphs represent the average optical density at 
450 nm (n = 4) for (a) A52 cells at 24 h; (b) A52 cells at 48 h; (c) Huh7 cells at 24 h; and (d) Huh7 cells at 48 h, 
after drug treatments. Tumoursphere number represents, (e) A52 cells, and (f) Huh7 cells grown in media 
containing 5 mM glucose or 5 mM fructose with or without 10, 25, or 50 μM of NCT-503 and/or Physcion. Data 
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7-AAD in fructose treated Huh7 cells (Fig. 4k,l), and only small peaks for A52 cells (Fig. 4i,j). This parallels the 
cell proliferation data, showing Huh7′s have markedly reduced cell proliferation after 48 h with fructose media 
(Fig. 3d), whereas A52 cells only had a slight reduction in growth in fructose (Fig. 3b).
NCT-503 and Physcion inhibit HCC tumour growth in vivo. Given these data and to give relevance to 
patients harbouring HCC, we initiated therapy of established 500 mm3 A52 and Huh7 subcutaneous tumours in 
mice fed either a normal or high fructose chow, and treated with either Physcion, or NCT-503, or in combination. 
After two weeks of treatment, A52 tumours had significantly reduced tumour growth in all treatment groups 
compared to the placebo group, in both the normal chow and fructose chow-fed mice (p < 0.0001; Fig. 5a,b). 
Moreover, the combination treatment and NCT-503 alone had a greater affect in reducing A52 tumour growth 
compared to Physcion alone (Fig. 5a). After the 14-day treatment there was no apparent differences in the rate 
of tumour growth between the A52 normal chow and fructose groups (Fig. 5a,b), and there was no significant 
difference in final tumour weights between the A52 treatment groups (Fig. 5e).
Similar to the in vitro results, in the normal chow fed mice Huh7 tumour growth was significantly inhibited 
by NCT-503 alone and the combination treatment group, while the Physcion treatment group had similar growth 
to placebo (p < 0.0001; Fig. 5c). In mice fed a high fructose chow, only the combination treatment significantly 
reduced tumour growth compared to the placebo group (p < 0.0001), and NCT-503 had little effect on reducing 
tumour growth (Fig. 5d). Similar to the A52 tumours, no reduction in the rate of Huh7 tumour growth was 
Figure 4.  A52 and Huh7 FACS analysis of apoptosis in glucose and fructose conditions. A52 and Huh7 cells 
were grown in either normal media, media containing 5 mM glucose, or 5 mM fructose for 48 h, and stained 
with 7-AAD and FITC-Annexin V to analyse apoptotic cell populations. For a positive control, cells were 
incubated with 1 mM  H2O2 for 2 h prior to FACS to induce apoptosis. Data represent the stained cell population 
percentages of 10,000 events for normal media (a,g), positive control (b,h), glucose media (c,i), and fructose 
media (d,j) for A52 and Huh7, respectively. Apoptosis positive cells are visible on the FITC axis in quadrants 
Q2 and Q3. Cells that are dead or in late stages of apoptosis with increased 7-AAD DNA binding are shown on 
the PerCP-Cy5-5 axis in quadrants Q1 and Q2. Histogram plots show cell counts for Annexin V and 7-AAD for 
A52 (e,f) and Huh7 (k,l), respectively.
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Figure 5.  Effect of NCT-503 and Physcion on glucose and fructose fed HCC tumour growth. Tumour growth 
curves of mice with (a) normal chow and A52 HCC cells, (b) high fructose chow and A52 HCC cells, (c) normal 
chow and Huh7 HCC cells, and (d) high fructose chow and Huh7 HCC cells, and treatment with placebo 
(black inverted triangles),40 mg/kg NCT-503 (blue circles), 20 mg/kg Physcion (red squares), and 40 mg/kg 
NCT-503 + 20 mg/kg Physcion (green upright triangles). Data represent the average daily tumour volume over 
a 14-day treatment period. (e) A52 and (f) Huh7 represent the final average tumour weight for groups fed a 
normal or high fructose diet. Groups: n = 6–12 tumours/group; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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observed in fructose-fed mice compared to the normal chow. In comparing final tumour weights, there were 
non-significant reductions for the normal chow NCT-503 and high fructose combinatorial groups, and no noted 
differences in the other groups (Fig. 5e,f). This is likely due to the variable and only moderate effects of the drugs 
on delaying tumour growth, particularly in the A52 model (Fig. 5a,b).
To gauge changes in tumour morphology A52 and Huh7 tumours were fixed and stained with haematoxylin 
and eosin. Regardless of diet or treatment, A52 tumours showed little change in tumour morphology (Fig. 6). In 
normal chow Huh7 tumours, there was a decreasing trend of haematoxylin staining in the drug-treated tumours 
(Fig. 7), however overall this was non-significant. Haematoxylin quantification showed there were no significant 
changes in haematoxylin ratios in the A52 or Huh7 tumours (Supplementary Figure 9). 
Discussion
To our knowledge, this is the first study examining the effects of fructose on HCC proliferation and growth in 
in vitro and in vivo models. We demonstrate that fructose significantly restricts HCC cell proliferation in vitro 
and causes metabolic adaptation in terms of protein expression of the PPP and SGS pathways. Through bioin-
formatic analyses of human data sets we find that increased G6PD and 6PGD gene expression associates with 
reduced survival. Hence, to address the activity of both the PPP and SGS pathways in HCC, we treated two 
subcutaneous tumour models for 2 weeks with a combinatorial strategy of Physcion and NCT-503. Together 
these two drugs can promote a significant reduction in HCC tumour growth.
The role of fructose in HCC development remains an unclear and controversial topic. While it is well estab-
lished that excess fructose can lead to fatty liver, insulin resistance and liver inflammation, it is unknown how 
fructose metabolism affects HCC development. Our work demonstrates that under in vitro conditions, fructose 
Figure 6.  A52 tumour histology treated with NCT-503 and Physcion. Haematoxylin and eosin images 
representing A52 pathology from each designated treatment group.
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sugar causes a significant retardation in murine and human HCC cell proliferation and tumoursphere formation. 
Fructose metabolism in hepatocytes is largely ATP-dependent and the breakdown of fructose into fructose-
1-phosphate causes rapid depletion of ATP in the  cells17. In addition, the depletion of cellular ATP indirectly 
causes the accumulation of uric acid, which stimulates the production of reactive oxygen species (ROS) and 
induces mitochondrial and endoplasmic reticulum oxidative  stress18. Therefore, the most likely cause for the 
dramatic reduction in cell proliferation and sphere number in fructose-fed HCC in vitro is due to increased 
cell death as a result of insufficient energy and ROS accumulation. In contrast, in the presence of high fructose 
feeding our in vivo models did not exhibit considerable changes in tumour growth. This could be a product 
of our chosen model where organs, such as the liver and muscle, are more involved in metabolizing fructose 
rather than the subcutaneous tumour, leading to a reduction in the expected deleterious effects of fructose, and 
that the subcutaneous tumour has developed an alternative pathway to support growth. It is also likely that the 
subcutaneous HCC tumour may be utilising adipose or muscle-derived compounds from surrounding tissue, 
such as lactate, alanine or pyruvate, to sustain growth during high-fructose  feeding19. This phenomenon could 
also partly explain the moderate effects the metabolism-inhibiting drugs had in vivo compared to in vitro. We 
briefly investigated this by examining cell proliferation of A52 and Huh7 cells exposed to NCT-503 and Physcion 
with or without the addition of amino acid supplementation. Our results show that the presence of amino acids 
in the cell media partly attenuated the inhibitory effects of NCT-503 and Physcion, in both glucose and fructose 
containing media (Supplementary Figure 10). These observations also support the concept that HCC metabolism 
is dynamic and adaptable to the tumour microenvironment.
Similarly, differential expression of metabolic enzymes has been noted between the primary tumour and 
metastases. By example, a recent study showed that liver metastases derived from colorectal cancer had increased 
Figure 7.  Huh7 tumour histology treated with NCT-503 and Physcion. Haematoxylin and eosin images 
representing Huh7 pathology from each designated treatment group.
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aldolase B expression, an enzyme involved in fructose metabolism. Moreover, the authors demonstrated that 
the metastases had reprogrammed metabolism to activate the fructose metabolic pathway, and a high fructose 
diet increased colorectal liver  metastasis20. Conversely, another study showed reduced aldolase B expression 
and fructose metabolism in primary HCC, and that overexpression of aldolase B reduced HCC metastasis, and 
was associated with improved patient  survival21. Additionally, studies have implicated the down-regulation 
of the fructose metabolic enzymes ketohexokinase-C and fructose-1,6-biphosphatase in promoting glycolysis 
and cancer growth, and suggest fructose metabolism is unfavourable in  HCC22–24. Here, in the context of our 
models we show that fructose causes a metabolic shift in the SGS and PPP pathways, but had no effect on HCC 
growth in vivo.
Our work has shown that a novel inhibitor of the SGS pathway, NCT-503, has the potential to inhibit HCC 
in vitro and in vivo. Only a few studies have investigated the use of NCT-503 in cancer growth inhibition. 
Nevertheless, the original work describing the action of NCT-503 on SGS inhibition, illustrated that NCT-503 
was only effective in PHGDH-dependent cell lines, with little or no impact on PHGDH-independent cell lines 
in vitro or in vivo25. This may in part explain the moderate effects of NCT-503 on HCC growth, and the variation 
we observed between our murine and human HCC models. Furthermore, this study showed that NCT-503 only 
affected glucose-derived production of serine, thereby inhibiting nucleotide synthesis originating from  glucose25. 
Additionally, when exogenous sources of serine were supplied, NCT-503 had a limited effect on inhibiting the 
production of  nucleotides25. This in part supports our results that demonstrate the strong impairment of HCC 
proliferation after treatment with NCT-503 in vitro with only moderate effects in vivo. Given glucose is the major 
source of fuel in vitro, HCC cells are more sensitive to SGS inhibition where glucose is the endogenous carbon 
source of glycolysis. However, considering our subcutaneous HCC models, it is likely that other exogenous 
sources of serine are available. This could in part explain why NCT-503 treatment was modestly effective in nor-
mal chow conditions in A52 and Huh7 tumours, and less effective when fed fructose. Similar results have been 
seen in another study, where NCT-503 treatment of HCC had only moderate effects in reducing subcutaneous 
tumour  growth15. This result could be expected, as our bioinformatics data suggests that even though the SGS 
pathway is downregulated in HCC patients, the relative expression appears to be unrelated to patient survival.
Recent studies have investigated the efficacy of Physcion in reducing HCC growth, and they contradict our 
current work. Studies on the action of Physcion with Huh7 cells, show that it reduces cell proliferation and 
subcutaneous tumour  growth13,26,27. Here, we demonstrate that Physcion promoted Huh7 cell growth at low con-
centrations in vitro, while having minimal effects on reducing tumour growth. Although we observed increases 
in haematoxylin staining in the centre of Physcion-treated tumours, to suggest cell death, the best explanation 
for our in vivo observations is that we evaluated tumour growth from 500 mm3 to better mimic the clinical situa-
tion. It is unclear why we observed an increase in HCC growth with Physcion in vitro, as this was an unexpected 
result and did not coincide with our protein expression data. Nonetheless, our bioinformatics data supports the 
concept that HCC patients have increased PPP activity and that high expression of the PPP enzymes G6PD and 
6PGD are associated with poor patient survival. Thus, targeting this pathway with Physcion or other inhibitors 
warrants further study, and could perhaps be more effectively used in earlier tumour development.
The limitation of this study is the moderate summative effects of NCT-503 and Physcion on HCC tumour 
growth. Although there was a substantial change in tumour growth rates, the tumour morphology is not sug-
gestive of extensive cell death. Therefore, the use of these drugs in HCC patients may only be of value in early 
stage HCC, as an adjuvant therapy or as a treatment to slow tumour growth in preparation for resection. For 
example, a study showed that Sorafenib resistant HCC have increased SGS activity and PHGDH expression, 
and subsequent combinatorial treatment with Sorafenib and NCT-503 may overcome HCC drug  resistance15. 
Similarly, another study showed the combination of Physcion and Sorafenib can inhibit HCC growth better than 
Sorafenib  alone28. In our study, we did not begin drug treatment until tumours were half the maximal size in order 
to mimic advanced HCC stages observed in the clinic. Moreover, given the apparent activity of these inhibitors 
using smaller subcutaneous tumours, perhaps our experimental approach of using more advanced HCCs should 
be considered as the status quo to more carefully evaluate new HCC targets. Taken together, these drugs may 
not induce regression in advanced tumours, but their combination may be more effective in early stage HCCs.
In conclusion, this study is the first to utilise a high fructose diet as means to manipulate the metabolic 
environment of HCC tumour growth. While many studies suggest high fructose promotes HCC development, 
our work indicates that fructose sugar may not entirely support HCC growth, and rather promotes metabolic 
adaptation in HCC tumours to utilise other carbon sources for energy. In this manner, we have shown that the 
activity of biosynthesis pathways involved in cancer cell growth, namely the SGS and PPP pathways, may be 
regulated through nutrition in HCC. Furthermore, manipulating the activity of the SGS and PPP allows for a 
unique metabolic environment that may be targeted with two novel inhibitors, NCT-503 and Physcion. The 
combination of NCT-503 and Physcion may be a novel treatment option for reducing HCC tumour growth, and 
warrants further investigation for their efficacy in a clinical setting.
Methods
Bioinformatics. RNASeq and patient outcome data was retrieved from the Broad GDAC Firehose via the 
Firebrowse data portal for the Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) cohort 
(https ://gdac.broad insti tute.org/); and use of the TCGA dataset was approved by the NIH as part of our project 
entitled #21012: "Investigating Novel Genes in HCC”. RNASeq data was normalised and differential expres-
sion of genes of interest between tumour and normal samples was evaluated using the R/Bioconductor package 
‘DESeq2’, with significant differential expression defined by an adjusted p value < 0.05. Based on gene expression 
in tumour tissue, patients were separated into cohorts with ‘High’, ‘Medium’, or ‘Low’ expression of each gene of 
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interest. Using patient outcome data, patient median survival was calculated and plotted using the R/Survival 
package, and significant difference in survival between cohorts was calculated using the log-rank test.
Cell Culture. Huh7 HCC cells were cultured in DMEM media supplemented with 10% heat-inactivated FBS 
and 1% (v/v) Penicillin–Streptomycin (Gibco). A52 HCC cells were used for a murine model of HCC as pub-
lished by  us16 and cultured in DMEM supplemented with 20% heat-inactivated FBS, 20 μg/L human epidermal 
growth factor (hEGF; Sigma Aldrich), 0.01 g/L insulin (Gibco), 0.01 g/L hydrocortisone, 1 mM phenobarbital, 
and 1% (v/v) Penicillin–Streptomycin. Cells were maintained at 37 °C in 5%  CO2.
Western blot. Cells and tumour tissue were lysed in RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% 
NP40, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM sodium orthovanadate, 50 mM NaFl, 1 mM sodium molyb-
date, 40 mM β-glycero-phosphate, 1 mM PMSF and 1/100 protease inhibitor cocktail) and protein concentration 
of lysates was determined using DC Protein Assay Kit (Bio-Rad). A total of 25 μg of protein was subjected to 
gel electrophoresis on a 10% SDS-PAGE gel and transferred to a PVDF membrane for one hour at 100 V. Mem-
branes were washed in TBST (Tris-buffered saline with 0.2% Tween 20) and blocked with 5% skim-milk/TBST. 
Membranes were incubated at 4 °C overnight with the following primary antibodies: G6PD (12263, Cell Signal-
ing), PSAT1 (ab96136, Abcam), PHGDH (ab13428, Abcam), transketolase (8616, Cell Signalling), transaldo-
lase (PA5-27614, ThermoFisher) and β-actin (A2228, Sigma Aldrich), Membranes were washed in TBST and 
incubated with their respective HRP-conjugated secondary antibodies (Sigma) in 5% skim-milk/TBST, washed 
with TBST and visualised using SuperSignal West Pico PLUS Chemiluminescent Substrate kit (34577, Ther-
moFisher). Original blot images can be found in Supplementary File 1. Densitometry analysis was performed 
using ImageJ and normalised to β-actin expression to determine the adjusted density value for each protein.
In vitro effect of fructose, NCT-503, and Physcion on HCC cell proliferation. Huh7 and A52 cells 
were seeded at 1.0 × 104 cells and 2.0 × 103 cells per well, respectively, in 96-well plates. After 24-h, the media 
was replaced with fresh media containing either standard media, glucose-free DMEM media (Gibco) supple-
mented with 10% heat-inactivated dialysed FBS, and 5 mM glucose or 5 mM fructose. For drug experiments, 
the media was supplemented with 10, 25, or 50 μM of NCT-503 (HY-101966, MedChemExpress) and/or Phy-
scion (M4323, Abmole). Amino acid media supplement was a 1/100 dilution of MEM non-essential amino acid 
solution (M7145, Sigma Aldrich). All treatment groups were conducted in quadruplicate, and cell proliferation 
was determined after 24-h and 48-h with a BrdU Colorimetric assay (Roche), according to the manufacturer’s 
protocol.
In vitro effect of NCT-503 and Physcion on HCC tumoursphere formation. Huh7 and A52 cells 
were cultured in sphere assay media consisting of 2% B27 Supplement (Gibco), 20  ng/mL hEGF, 10  ng/mL 
basic fibroblast growth factor (bFGF; Gibco), 2 μg/mL heparin (Sigma Aldrich), 5 μg/mL insulin, 0.5 μg/mL 
hydrocortisone, and 1% (v/v) Penicillin–Streptomycin. Huh7 and A52 cells were seeded at 3.0 × 104 cells per well 
in 6-well low attachment plates (Sigma Aldrich) and incubated at 37 °C in 5%  CO2 for seven days. Treatment 
groups included sphere formation in media containing either 5 mM glucose or fructose alone, or glucose or 
fructose-supplemented media containing NCT-503 and/or Physcion. After 7 days, tumourspheres were counted.
FACS analysis. Huh7 and A52 cells were cultured in normal media (negative control), glucose media, or 
fructose media, as described above, for 48 h. For a positive control, fresh media containing 1 mM  H2O2 was 
supplied to A52 and Huh7 cells 2  h prior to experimentation to induce apoptosis. For apoptotic cell analy-
sis, cells were harvested with Accutase and stained with FITC-Annexin V (640906, BioLegend) and 7-AAD 
(7-aminoactinomycin D; 420404, BioLegend). Flow cytometry was performed using a BD LSRFortessa and BD 
FACSDIVA software (Version 6.1.3, BD Sciences). The FITC channel and PerCP-Cy5-5 channel were used for 
Annexin V and 7-AAD emission wavelengths, respectively. A total of 10,000 events were recorded for each 
group and FlowJo version 10.6.2 was used for data analysis and graphing. Quadrant placement (FITC-A versus 
PerCP-Cy5-5) was based on unstained and single stained cells from the negative and positive control treatment 
groups, and represent Q1 (non-specific cell death), Q2 (late stage apoptosis), Q3 (early stage apoptosis) and Q4 
(viable cells).
In vivo effect of NCT-503 and Physcion in glucose and fructose-fed HCC tumours. All animal 
experimental protocols were approved by the James Cook University Animal Welfare and Ethics committee 
(A2238). All experiments were performed in accordance with relevant guidelines and regulations. Male C57BL/6 
mice or male BALB/cFox1nu mice aged 6–12 weeks were given ad libitum access to food and water. Huh7 and 
A52 HCC tumour growth was evaluated in male BALB/cFox1nu and male C57BL/6 mice, respectively. Mice 
were fed isocaloric diets of a normal chow (AIN93G, Specialty Feeds; protein 19.4%, fats 7%, carbohydrate 
56.8%, crude fibre 7% and acid detergent fibre 7%) or a 60% fructose chow (SF03-018, Specialty Feeds; where 
fructose replaced sucrose, dextrinised starch and starch) for three weeks prior to HCC cells (2.5 × 106 cells in 
200 μL PBS/ECM gel; Sigma Aldrich) being bilaterally and subcutaneously injected into the rear flanks of the 
mice (n = 6–12 each group). For drug experiments, tumours were allowed to grow to a half-maximum size of 
500 mm3 to mimic tumours observed in the clinic prior to drug treatment. Mice were randomly allocated into 
the following treatment groups: (i) placebo (vehicle only), (ii) 40 mg/kg NCT-503 (dissolved in 60% of 30% 
2-hydroxypropyl-β-cyclodextrin, 30% PEG-300, and 10% ethanol), (iii) 20 mg/kg Physcion (dissolved in 10% 
DMSO and 90% saline), or (iv) 40 mg/kg NCT-503 and 20 mg/kg Physcion. Each drug or placebo was admin-
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istered daily as a 200 μL intraperitoneal injection for a 14-day treatment period or until the tumour reached a 
maximum volume of 1000 mm3. Tumour volume was measured daily with a digital caliper and calculated using 
the following formula: V = (L × W2/2), where V is volume, L is length, and W is width. To determine differences 
in tumour growth non-liner regression was performed with the Prism program. At experiment end the tumours 
were harvested, weighed and snap-frozen in liquid nitrogen or fixed in 4% paraformaldehyde for histology, 
stained with haematoxylin and eosin, and scanned with the Aperio ImageScope. The haematoxylin ratio was 
determined with ImageJ.
Data and statistical analysis. All data are presented as mean ± standard error. Data from different experi-
mental groups were compared using one-way and two-way ANOVA and Tukey’s multiple comparison tests. For 
densitometry analysis, the 2 treatment groups were compared using the Mann–Whitney t test.
Statistical significance was defined as p < 0.05.
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